Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arcturus Therapeutics Holdings Inc (NQ:ARCT)

7.230 -0.300 (-3.98%)
Streaming Delayed Price Updated: 3:29 PM EDT, Jun 22, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arcturus Therapeutics Holdings Inc

< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Understanding Arcturus Therapeutics's Unusual Options Activity ↗
On Tuesday, shares of Arcturus Therapeutics (NASDAQ:ARCT)... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
Gainers Arcturus Therapeutics (NASDAQ:ARCT) stock moved upwards by 29.05% to $44.73 during Tuesday's regular session. As of 12:35 EST, Arcturus Therapeutics's... 
Via Benzinga
News headline image
Mid-Day Market Update: Crude Oil Down 2%; Arcturus Therapeutics Shares Spike Higher ↗
Midway through trading Tuesday, the Dow traded up 0.11% to 34,878.06 while the NASDAQ fell 0.37% to 14,626.97. The S&P also fell, dropping 0.01% to 4,386.68. The U.S. has the... 
Via Benzinga
Topics Stocks
News headline image
Why Arcturus Therapeutics Stock Is Soaring Today ↗
The company received a green light to advance two COVID-19 vaccine candidates into clinical testing in a second country. 
Via The Motley Fool
News headline image
21 Stocks Moving in Tuesday's Pre-Market Session ↗
Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares rose 46% to $6.35 in pre-market trading following Form 4 filing from the company’s 10% owner, Retail Ecommerce... 
Via Benzinga
News headline image
48 Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers Wilhelmina International, Inc. (NASDAQ: WHLM) shares jumped 64.4% to $7.15 after a Form 4 filing from the company showed 10% shareholder Retail Ecommerce Ventures... 
Via Benzinga
News headline image
Arcturus Announces Approval of Singapore Clinical Trial Application to Advance ARCT-154 and ARCT-165, Next Generation STARR™ mRNA Vaccines Targeting SARS-CoV-2 Variants of Concern, in a Phase 1/2 Study
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 2) Absci, CORP (NASDAQ: ABSI) (... 
Via Benzinga
News headline image
10 Health Care Stocks Showing Unusual Options Activity In Today's Session ↗
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
News headline image
Arcturus' COVID-19 mRNA Vaccine Candidate To Target Variants, Trial To Start In Vietnam ↗
The Vietnam Ministry of Health has signed off Arcturus Therapeutics Holdings Inc's (NASDAQ: ARCT) Clinical Trial Application (CTA) to advance ARCT-154 COVID19... 
Via Benzinga
News headline image
Arcturus Therapeutics Stock Jumps On Establishment Of COVID-19 Vaccine Plant In Vietnam ↗
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) has collaborated with Vinbiocare to establish a manufacturing facility in Vietnam for its... 
Via Benzinga
News headline image
Arcturus Announces Approval of a Clinical Trial Application to Advance ARCT-154, a Next Generation STARR™ mRNA Vaccine Targeting the SARS-CoV-2 Delta Variant and Other Variants of Concern
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics Collaborates with Vingroup to Establish Manufacturing Facility in Vietnam for Arcturus’ Investigational mRNA Vaccines for COVID-19
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Announces Regulatory Approval to Proceed with Phase 2 Study of ARCT-810 mRNA Therapeutic Candidate for Ornithine Transcarbamylase (OTC) Deficiency
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Report Second Quarter 2021 Financial Results and Provide Corporate Update on August 9, 2021
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For July 2, 2021 ↗
Upgrades According to Deutsche Bank, the prior rating for Encompass Health Corp (NYSE: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers Alector (NASDAQ:ALEC) stock moved upwards by 39.93% to $31.36 during Friday's pre-market session. The market value of their outstanding shares is at $2.5... 
Via Benzinga
News headline image
Return On Capital Employed Overview: Arcturus Therapeutics ↗
During Q1, Arcturus Therapeutics's (NASDAQ:ARCT) reported sales totaled $2.13 million. Despite a 85.53% in earnings, the company posted a loss of $57.67 million. In Q4, Arcturus... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 21, 2021 ↗
Upgrades B of A Securities upgraded the previous rating for Cimarex Energy Co (NYSE: 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
Gainers MediciNova (NASDAQ:MNOV) shares moved upwards by 50.79% to $5.67 during Monday's pre-market session. The market value of their outstanding shares is at $276.5... 
Via Benzinga
News headline image
10 Biggest Price Target Changes For Monday ↗
SVB Leerink raised Natera, Inc. (NASDAQ:NTRA) pr... 
Via Benzinga
News headline image
Arcturus Therapeutics to Present at Upcoming Investor and Scientific Conferences
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
Looking Into Arcturus Therapeutics's Return On Capital Employed ↗
In Q1, Arcturus Therapeutics (NASDAQ:ARCT) posted sales of $2.13 million. Earnings were up 85.53%, but Arcturus Therapeutics still reported an overall loss of $57.67 million.... 
Via Benzinga
News headline image
High Flyers At Much Lower Altitudes ↗
Stocks with extreme valuations have taken a serious haircut since the space peaked on February 22nd. 
Via Talk Markets
News headline image
Arcturus Therapeutics: Q1 Earnings Insights ↗
Shares of Arcturus Therapeutics (NASDAQ:ARCT) fell in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were down 220.90% over... 
Via Benzinga
News headline image
Arcturus Therapeutics Announces First Quarter 2021 Company Overview and Financial Results and Provides New Clinical Data
From Arcturus Therapeutics Holdings Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13) Alexion Pharmaceuticals, Inc... 
Via Benzinga
News headline image
The Daily Biotech Pulse: Minerva, InflaRx Report Positive Data Readouts, Lucira COVID-19 Test Kit Available On Amazon, Decision Day For Heron ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 11) HOOKIPA Pharma Inc. (NASDAQ... 
Via Benzinga
News headline image
The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -... 
Via Benzinga
< Previous 1 2
...
6 7 8 9 10 11 12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.